Beta Drugs Ltd Q4 FY2025 Concall Summary

Key Takeaways

• Audit disruption masked underlying momentum: Revenue would have exceeded Rs. 375 crores but for a 10-day Mexico audit that halted production and cost Rs. 7-8 crores in lost sales. Branded sales still crossed Rs. 100 crores for the first time.
• Exports are the growth engine: Exports grew 73% to nearly Rs. 80 crores, fueled by new approvals (COFEPRIS, ZaZiBoNa) and a stated intent to 3x export sales in 2-3 years.
• Cosmetology turned the corner: The division hit monthly break-even, doubled its prescriber base, and is expected to post profits by September, removing a persistent drag.
• Mainboard migration is imminent: Documentation is filed and NSE approval is expected within 2-3 months, which will trigger quarterly reporting and potentially broaden the investor base.
• What to watch next quarter: Whether the Mexico audit's lost sales are recouped, the pace of dossier filings converting to registrations, and the actual timing of the Mainboard migration and its effect on reporting frequency.

The Mexico Audit: What Happened and What It Cost

• Production halted for 7-8 days: A scheduled audit from Mexico, combined with the Holi holiday, stopped production in both the API and formulation plants. Orders were in hand but could not be executed.
• Lost sales quantified: Management estimates Rs. 7-8 crores of revenue was lost in Q4 FY25, which would have pushed consolidated revenue past Rs. 375 crores.
• Audit concluded successfully: The Mexico audit was completed for both API and formulation, and the API plant will receive PIC/S approval, strengthening the export compliance profile.

Rahul Batra: "We would have achieved a top line of more than Rs. 375 crores, but in March, we had an audit from Mexico, which took almost 10 days of our production, with a very low production in both API and formulation plant."

Export & Regulatory Pathway

• Exports surged 73% to Rs. 80 crores: Growth was driven by new approvals from COFEPRIS and ZaZiBoNa, with a strategic focus on LATAM and APAC regions. A new hire with vast international API oncology experience has joined to accelerate this push.
• Dossier engine is running hot: 48 new registrations were received, close to 130 new dossiers were filed, and more than 200 additional dossiers are being prepared for filing in the next 4-12 months.
• Europe is a 2.5-year story: The API plant has been upgraded for Europe approval, dossiers will be ready in 3 months, and an EU GMP audit is expected between October and December this year. Revenue from Europe will start after 2.5 years, with the certificate taking 6 months post-audit.
• Mexico pipeline building: 12 dossiers under evaluation will be submitted in the next 2-3 months, with another 12-15 in the pipeline to follow in the same window.
• Regulated market revenue timing: Revenue from regulated markets where licenses were received in FY24 and FY25 is expected to pick up in FY27, starting May/June 2027.

Rahul Batra: "We are intent to 3 times our sales in next 2 to 3 years down the line from the export side."

Branded Domestic Business

• Branded sales crossed Rs. 100 crores: Own brand sales reached Rs. 103 crores, growing 25.27% YoY, with the first brand crossing Rs. 8 crores being NDDS, launched for the first time in India.
• Oral oncology dominates the mix: Contribution of oral therapy (NIBs, TKIs, Supportive Therapy) rose to 48% of total branded sales, reflecting the strategic shift toward higher-value oral oncology.
• NDDS is expanding markets, not just taking share: The launch of Megestrol acetate NDDS grew the total market from Rs. 6 crores to over Rs. 16 crores, with Beta holding the lion's share, demonstrating a market-expansion playbook rather than pure substitution.
• Product launch cadence: 6 products were launched apart from 2 NDDS, with another 6 in process for this financial year, plus 2 more NDDS to be launched this year and 2 more in FY27, all first time in India.

Ashutosh Shukla: "The NDDS which we have launched last year, we have expanded the overall market size. For an example, Megestrol acetate, the total market size was close to Rs. 6 crores. After the launch of our brand, the total market size is now more than INR 16 crores, out of which we have the lion share."

Cosmetology & Derma: The Turnaround

• Cosmetology reached monthly break-even: EBITDA loss narrowed from Rs. 4 crores to Rs. 3 crores, with break-even achieved in the last month of the quarter. The prescriber base doubled from 1,200 to 2,600 and PCPM rose from Rs. 75,000 to Rs. 1.25 lakh.
• Profitability expected by September: Management guided that the Cosmetology division will post profits by September, supported by an in-licensing deal with an Italian company for fillers, with registrations received and commercialization in the next 2 months.
• Derma grew 80% but remains loss-making: Derma revenue reached Rs. 12.30 crores, though it is still at an EBITDA loss. Guidance calls for Rs. 18-20 crores this year, Rs. 30 crores next financial year, and Rs. 45-50 crores thereafter.

CDMO, API & Backward Integration

• CDMO grew 5%, in line with the guided 5-10% range: Beta remains the preferred choice for Indian MNCs for oncology cytotoxics manufacturing, with 3 new clients added this year including Glenmark, Intas, Alkem, Cadila, and Torrent.
• API revenue flat at Rs. 20 crores: The flat performance reflects major internal consumption rather than weak external demand. Four new API molecules were commercialized last year, with 6 more in process to launch, followed by 20 new molecules in the next 3-5 years.
• Backward integration to reduce China dependency: The company is looking to establish a new plant for intermediates, manufacturing from the basic KRM stage. In the next couple of months, something will be shaped up and the company will have some plant for intermediates.
• R&D output on a lean budget: R&D spend of approximately 2% with a 10-person team drove development of 2 NDDS and multiple new molecules, with work underway on immunotherapies and a potential generic mAb launch by 2028.

Financials: Costs, Margins & Capital Allocation

• Gross margin stable, not declining: Management pushed back on a sequential decline question, stating gross margin was 52% in H1 FY25 and more than 52.5% in H2, a marginal improvement.
• Three cost lines rose for identifiable reasons: Employee cost grew 31% YoY partly due to Derma hires; depreciation rose from ~Rs. 10 crores to ~Rs. 13 crores as CapEx added late last year now carries a full charge; financial cost increased Rs. 4 crores due to a provision for convertible debentures from the preferential issue, which carry an 18-month coupon.
• No M&A on the table: Major capital allocation will go toward a new corporate building consolidating office, R&D, and regulatory functions, plus the intermediates plant. If a good branded business comes along, the company will evaluate, but nothing is active.
• Mainboard migration triggers quarterly reporting: If migration happens in June, July results will be out; if in July, half-yearly results will apply, then every 3 months. Management will try to implement quarterly results from this quarter itself.

Guidance & Commitments

Key Metrics